Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, BBOT, Parabilis Medicines, RAPP, ERAS, and represent 35.74% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: Parabilis Medicines (+$126M), CLYM (+$28M), SYRE (+$20M), DFTX (+$19M), ASND (+$13M), BHVN (+$13M), ANL (+$12M), Kailera Therapeutics (+$12M), ELVN (+$7.6M), IBIO (+$6.2M).
- Started 13 new stock positions in Quince Therapeutics, Parabilis Medicines, BOLD, CLYM, DFTX, Odyssey Therapeutics, ASND, IBIO, Research Alliance Corp Iii, SYRE. Kailera Therapeutics, ELVN, ALT.
- Reduced shares in these 10 stocks: PRAX (-$82M), Centessa Pharmaceuticals (-$42M), MBX (-$32M), EWTX (-$31M), OLMA (-$28M), MLTX (-$25M), MAZE (-$22M), BBIO (-$22M), Ascendis Pharma A S (-$22M), DNTH (-$20M).
- Sold out of its positions in Ascendis Pharma A S, AXSM, Centessa Pharmaceuticals, CNTX, MAZE, GLUE, RLYB, TERN, ZURA.
- Cormorant Asset Management was a net seller of stock by $-277M.
- Cormorant Asset Management has $2.0B in assets under management (AUM), dropping by -1.99%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 50 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 11.0 | $214M | -27% | 640k | 334.79 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 7.0 | $136M | 18M | 7.62 |
|
|
| Parabilis Medicines | 6.5 | $126M | NEW | 4.6M | 27.37 |
|
| Rapport Therapeutics (RAPP) | 5.7 | $111M | -10% | 2.7M | 41.67 |
|
| Erasca (ERAS) | 5.6 | $110M | +3% | 6.0M | 18.32 |
|
| Edgewise Therapeutics (EWTX) | 5.2 | $102M | -23% | 2.5M | 40.63 |
|
| Eyepoint Com New (EYPT) | 5.1 | $100M | -15% | 7.0M | 14.30 |
|
| Alumis (ALMS) | 4.7 | $93M | -16% | 3.3M | 28.14 |
|
| Abivax Sa Sponsored Ads (ABVX) | 4.6 | $90M | -11% | 675k | 133.26 |
|
| Dianthus Therapeutics (DNTH) | 3.7 | $73M | -21% | 750k | 97.48 |
|
| Bright Minds Biosciences Com New (DRUG) | 3.2 | $63M | -15% | 900k | 70.20 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 3.2 | $62M | -28% | 3.2M | 19.47 |
|
| Bioage Labs (BIOA) | 3.0 | $59M | -17% | 2.4M | 24.51 |
|
| Oruka Therapeutics (ORKA) | 2.6 | $51M | 533k | 95.17 |
|
|
| Adlai Nortye Sponsored Ads (ANL) | 2.3 | $46M | +37% | 4.0M | 11.50 |
|
| Bridgebio Pharma (BBIO) | 2.1 | $41M | -35% | 550k | 74.48 |
|
| Tango Therapeutics (TNGX) | 2.1 | $41M | -8% | 1.3M | 31.26 |
|
| Biohaven (BHVN) | 2.0 | $39M | +48% | 2.6M | 14.88 |
|
| Agomab Therapeutics Nv Sponsored Ads (AGMB) | 1.6 | $32M | 2.5M | 12.98 |
|
|
| Mbx Biosciences (MBX) | 1.6 | $30M | -50% | 550k | 55.20 |
|
| Eliem Therapeutics (CLYM) | 1.4 | $28M | NEW | 2.1M | 13.04 |
|
| Olema Pharmaceuticals (OLMA) | 1.4 | $27M | -51% | 2.2M | 12.51 |
|
| Galecto (DMRA) | 1.3 | $26M | -34% | 1.0M | 26.01 |
|
| Pharvaris N V (PHVS) | 1.3 | $26M | -25% | 750k | 34.58 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $22M | 2.3M | 9.38 |
|
|
| Spyre Therapeutics Com New (SYRE) | 1.0 | $20M | NEW | 225k | 88.78 |
|
| Definium Therapeutics Com Shs (DFTX) | 1.0 | $19M | NEW | 400k | 47.04 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.9 | $17M | -47% | 500k | 33.89 |
|
| Roivant Sciences SHS (ROIV) | 0.9 | $17M | -36% | 475k | 35.39 |
|
| Cabaletta Bio (CABA) | 0.8 | $16M | -9% | 5.0M | 3.11 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 0.7 | $14M | 1.3M | 10.64 |
|
|
| Ascendis Pharma A/s Ord Shs (ASND) | 0.7 | $13M | NEW | 50k | 266.72 |
|
| Kailera Therapeutics Common Stock | 0.6 | $12M | NEW | 550k | 22.03 |
|
| Insmed Com Par $.01 (INSM) | 0.4 | $8.0M | -60% | 75k | 106.62 |
|
| Faeth Therapeutics Com New (FTH) | 0.4 | $7.7M | +235% | 1.0M | 7.45 |
|
| Enliven Therapeutics (ELVN) | 0.4 | $7.6M | NEW | 150k | 50.75 |
|
| Tarsus Pharmaceuticals (TARS) | 0.3 | $6.3M | -55% | 100k | 62.94 |
|
| Ibio Com New (IBIO) | 0.3 | $6.2M | NEW | 3.6M | 1.75 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.2 | $4.7M | -50% | 125k | 37.42 |
|
| Arcutis Biotherapeutics (ARQT) | 0.2 | $4.6M | -61% | 175k | 26.22 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.2 | $4.1M | -50% | 50k | 81.51 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.2 | $4.0M | -57% | 75k | 53.67 |
|
| Research Alliance Corp Iii Ord Shs Cl A | 0.2 | $4.0M | NEW | 370k | 10.70 |
|
| Cogent Biosciences (COGT) | 0.2 | $3.9M | -50% | 100k | 38.70 |
|
| Altimmune Com New (ALT) | 0.2 | $3.8M | NEW | 1.3M | 3.04 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.2 | $3.6M | -42% | 200k | 17.96 |
|
| Odyssey Therapeutics Common Stock | 0.2 | $3.3M | NEW | 175k | 18.71 |
|
| Vaxcyte (PCVX) | 0.1 | $2.9M | -50% | 50k | 58.13 |
|
| Boundless Bio (BOLD) | 0.1 | $2.5M | NEW | 1.0M | 2.50 |
|
| Quince Therapeutics | 0.0 | $100k | NEW | 5.5k | 18.19 |
|
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2026 Q2 filed Aug. 14, 2026
- Cormorant Asset Management 2026 Q1 filed May 15, 2026
- Cormorant Asset Management 2025 Q4 filed Feb. 17, 2026
- Cormorant Asset Management 2025 Q3 filed Nov. 14, 2025
- Cormorant Asset Management 2025 Q2 filed Aug. 14, 2025
- Cormorant Asset Management 2025 Q1 filed May 15, 2025
- Cormorant Asset Management 2024 Q4 filed Feb. 14, 2025
- Cormorant Asset Management 2024 Q3 filed Nov. 14, 2024
- Cormorant Asset Management 2024 Q2 filed Aug. 14, 2024
- Cormorant Asset Management 2024 Q1 filed May 15, 2024
- Cormorant Asset Management 2023 Q4 filed Feb. 14, 2024
- Cormorant Asset Management 2023 Q3 filed Nov. 14, 2023
- Cormorant Asset Management 2023 Q2 filed Aug. 14, 2023
- Cormorant Asset Management 2023 Q1 filed May 15, 2023
- Cormorant Asset Management 2022 Q4 filed Feb. 14, 2023
- Cormorant Asset Management 2022 Q3 filed Nov. 14, 2022